# A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes

> **NCT05297045** · PHASE2 · TERMINATED · sponsor: **Regor Pharmaceuticals Inc.** · enrollment: 17 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** RGT001-075
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05297045
- **Lead sponsor:** Regor Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-03-29
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Terminated due to financial constraint.
- **Last updated:** 2023-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05297045

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05297045, "A Study of Oral GLP1RA RGT001-075 in Adults With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05297045. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*